Why Aytu BioScience Stock Remains a Promising Coronavirus Play
Aytu BioScience is a coronavirus play after moving into testing and treatment.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Aytu BioScience Inc. (NASDAQ: AYTU) stock has been a huge beneficiary of the coronavirus pandemic. In fact, Aytu BioScience stock is up 52% year to date and up over 100% in the past six months alone.
For those late to the party, Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility.
The company only branched out into the COVID-19 testing business back in February. Since then Aytu BioScience has expanded its reach with multiple deals.
Sterling Medical Deal
Back in late April, the company signed an agreement with Sterling Medical Devicese to finalize the development of its Healight platform technology. Basically, this is a novel endotracheal catheter that emits ultraviolet light and is a potential treatment for the coronavirus.
[nativounit]
Aytu thinks that the Healight platform technology will affect outcomes for critically ill patients with COVID-19 and other infections. The company, with support from Cedars-Sinai, is working with the U.S. Food and Drug Administration (FDA) to determine an expedited regulatory process for Healight. The goal is to enable near-term use of the technology, initially as a coronavirus intervention for critically ill intubated patients.
[recirclink id=710707]
Other Developments
Separately, Aytu announced an agreement with the Singapore-based firm Biolidics for the exclusive U.S. distribution rights to Biolidics’s COVID-19 IgG/IgM Rapid Test. As a result, the Denver-based company purchased 500,000 tests immediately and committed to purchasing at least 1.25 million more in the first three months of the agreement.
Aytu received 100,000 test kits on April 1, prior to the agreement with Biolidics. The Denver Police Department bought the first 2,750 of these to screen the city’s first responders. On April 15, Aytu said that it had sold all 100,000 tests and was awaiting delivery of more.
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
